These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 16685387)
1. GEP associates with wild-type p53 in hepatocellular carcinoma. Cheung ST; Wong SY; Lee YT; Fan ST Oncol Rep; 2006 Jun; 15(6):1507-11. PubMed ID: 16685387 [TBL] [Abstract][Full Text] [Related]
2. Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. Cheung ST; Wong SY; Leung KL; Chen X; So S; Ng IO; Fan ST Clin Cancer Res; 2004 Nov; 10(22):7629-36. PubMed ID: 15569995 [TBL] [Abstract][Full Text] [Related]
3. Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma. Moriyama Y; Nishiguchi S; Tamori A; Koh N; Yano Y; Kubo S; Hirohashi K; Otani S Clin Cancer Res; 2001 May; 7(5):1293-8. PubMed ID: 11350897 [TBL] [Abstract][Full Text] [Related]
4. High levels of p53 protein expression do not correlate with p53 mutations in hepatocellular carcinoma. Anzola M; Saiz A; Cuevas N; Lopez-Martinez M; Martinez de Pancorbo MA; Burgos JJ J Viral Hepat; 2004 Nov; 11(6):502-10. PubMed ID: 15500550 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of p53 in a large series of patients with hepatocellular carcinoma: a clinicopathological correlation. Caruso ML; Valentini AM Anticancer Res; 1999; 19(5B):3853-6. PubMed ID: 10628323 [TBL] [Abstract][Full Text] [Related]
6. RNA interference against granulin-epithelin precursor prevents hepatocellular carcinoma growth: its application as a therapeutic agent. Park MY; Park YS; Nam JH Int J Oncol; 2011 Oct; 39(4):853-61. PubMed ID: 21701774 [TBL] [Abstract][Full Text] [Related]
7. Binding of wild-type p53 by topoisomerase II and overexpression of topoisomerase II in human hepatocellular carcinoma. Yuwen H; Hsia CC; Nakashima Y; Evangelista A; Tabor E Biochem Biophys Res Commun; 1997 May; 234(1):194-7. PubMed ID: 9168988 [TBL] [Abstract][Full Text] [Related]
8. Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma. Hsia CC; Nakashima Y; Thorgeirsson SS; Harris CC; Minemura M; Momosaki S; Wang NJ; Tabor E Oncol Rep; 2000; 7(2):353-6. PubMed ID: 10671685 [TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis by pectenotoxin-2 is mediated with the induction of DR4/DR5, Egr-1 and NAG-1, activation of caspases and modulation of the Bcl-2 family in p53-deficient Hep3B hepatocellular carcinoma cells. Shin DY; Kim GY; Kim ND; Jung JH; Kim SK; Kang HS; Choi YH Oncol Rep; 2008 Feb; 19(2):517-26. PubMed ID: 18202802 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the expression of beta-catenin in hepatocellular carcinoma in areas with high and low levels of exposure to aflatoxin B1. Chen Ban K; Singh H; Krishnan R; Fong Seow H J Surg Oncol; 2004 Jun; 86(3):157-63. PubMed ID: 15170655 [TBL] [Abstract][Full Text] [Related]
11. Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity. Cheung PF; Yip CW; Wong NC; Fong DY; Ng LW; Wan AM; Wong CK; Cheung TT; Ng IO; Poon RT; Fan ST; Cheung ST Cancer Immunol Res; 2014 Dec; 2(12):1209-19. PubMed ID: 25315249 [TBL] [Abstract][Full Text] [Related]
12. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations. Kubicka S; Trautwein C; Niehof M; Manns M Hepatology; 1997 Apr; 25(4):867-73. PubMed ID: 9096590 [TBL] [Abstract][Full Text] [Related]
13. Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Ho JC; Ip YC; Cheung ST; Lee YT; Chan KF; Wong SY; Fan ST Hepatology; 2008 May; 47(5):1524-32. PubMed ID: 18393387 [TBL] [Abstract][Full Text] [Related]
14. Wild type p53 increased chemosensitivity of drug-resistant human hepatocellular carcinoma Bel7402/5-FU cells. Li YX; Lin ZB; Tan HR Acta Pharmacol Sin; 2004 Jan; 25(1):76-82. PubMed ID: 14704126 [TBL] [Abstract][Full Text] [Related]
15. Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma. Volkmann M; Schiff JH; Hajjar Y; Otto G; Stilgenbauer F; Fiehn W; Galle PR; Hofmann WJ J Mol Med (Berl); 2001 Oct; 79(10):594-600. PubMed ID: 11692157 [TBL] [Abstract][Full Text] [Related]
16. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. Tseng PL; Tai MH; Huang CC; Wang CC; Lin JW; Hung CH; Chen CH; Wang JH; Lu SN; Lee CM; Changchien CS; Hu TH J Surg Oncol; 2008 Oct; 98(5):349-57. PubMed ID: 18646041 [TBL] [Abstract][Full Text] [Related]
17. RASSF1A expression inhibits the growth of hepatocellular carcinoma from Qidong County. Xue WJ; Li C; Zhou XJ; Guan HG; Qin L; Li P; Wang ZW; Qian HX J Gastroenterol Hepatol; 2008 Sep; 23(9):1448-58. PubMed ID: 17683489 [TBL] [Abstract][Full Text] [Related]
18. TIP30 mutant derived from hepatocellular carcinoma specimens promotes growth of HepG2 cells through up-regulation of N-cadherin. Jiang C; Pecha J; Hoshino I; Ankrapp D; Xiao H Cancer Res; 2007 Apr; 67(8):3574-82. PubMed ID: 17440068 [TBL] [Abstract][Full Text] [Related]
19. Expression and role of SIRT1 in hepatocellular carcinoma. Choi HN; Bae JS; Jamiyandorj U; Noh SJ; Park HS; Jang KY; Chung MJ; Kang MJ; Lee DG; Moon WS Oncol Rep; 2011 Aug; 26(2):503-10. PubMed ID: 21567102 [TBL] [Abstract][Full Text] [Related]
20. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma. Lin SY; Pan HW; Liu SH; Jeng YM; Hu FC; Peng SY; Lai PL; Hsu HC Clin Cancer Res; 2008 Aug; 14(15):4814-20. PubMed ID: 18676753 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]